Drugs / COVID-eVax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04788459 | Feb → Dec 2021 | COVID-19 | Takis | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-01-11 | Rottapharm Biotech | Results COVID-eVax PHASE 1 CLINICAL TRIAL RESULTS PUBLISHED rottapharmbiotech.com ↗
COVID-eVax was well tolerated and induced an immune response (binding antibodies and/or T cells) in up to 90% of the volunteers at the highest dose. |
| 2021-09-07 | Rottapharm Biotech | Results Takis and Rottapharm Biotech announce favourable preliminary results from the phase I clinical trial of COVID-eVax, a DNA-based vaccine candidate against COVID-19 rottapharmbiotech.com ↗
COVID-eVax was well tolerated and induced an immune response (humoral and/or cell-mediated response) with all tested doses (0.5 mg, 1 mg and 2 mg, administered as prime-boost regimen). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-01-11 | Rottapharm Biotech | COVID-eVax PHASE 1 CLINICAL TRIAL RESULTS PUBLISHED rottapharmbiotech.com ↗ |
| 2021-09-07 | Rottapharm Biotech | Takis and Rottapharm Biotech announce favourable preliminary results from the phase I clinical trial of COVID-eVax, a DNA-based vaccine candidate against COVID-19 rottapharmbiotech.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVID-eVax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04788459 ↗ |
| Modality | Vaccine | “DNA plasmid-based vaccine” NCT04788459 ↗ |
| Route | Intramuscular | “intramuscular (IM) injection” NCT04788459 ↗ |